Cigna earnings beat by $0.04, revenue topped estimates
TriMas Corp. (TRS) reported Q4 EPS of $0.62, $0.04 worse than the analyst estimate of $0.66. Revenue for the quarter came in at $203.3 million versus the consensus estimate of $211.85 million.
GUIDANCE:
TriMas Corp. sees FY2023 EPS of $2.00-$2.20, versus the consensus of $2.14.
- The Company expects TriMas' 2023 consolidated sales to increase 10% to 15% compared to 2022. The Company expects full year 2023 adjusted diluted earnings per share(2) to be between $2.00 to $2.20 per share. For first quarter 2023, adjusted diluted earnings per share(2) is anticipated to be in the range of $0.24 to $0.28. In addition, the Company is targeting full year 2023 Free Cash Flow(4) to be greater than 100% of net income.
- "While we do not customarily provide quarterly guidance, we believe it prudent to provide first quarter guidance today given it is not indicative of our expectations for the remainder of 2023. We are forecasting a demand recovery within TriMas Packaging as we move through 2023, as our customers continue to work through high inventory levels, and we collectively assess changes in consumer confidence. As such, we anticipate first quarter EPS to be lower than the prior year quarter, and are forecasting sequential improvement in the second and third quarters driven by a reversion to a more normalized seasonal selling period, which did not occur in 2022. We remain excited about our prospects for the future, and believe our strategy to deploy our strong cash flow to augment TriMas' core growth with acquisitions will continue to drive long-term value for our shareholders," commented Amato.